ËÑË÷½á¹û°üº¬ 21 ?FDA? µÄÄÚÈÝ

?ÃÀµÏÎ÷×÷ΪÁìŵҽҩµÄºÏ×÷»ï°é£¬ÎªSLN12140ÌṩÁËÌåÍâҩЧ¡¢Ò©´ú¡¢°²ÆÀµÈһվʽÁÙ´²Ç°Ñз¢·þÎñ£¬Îª¸ÃÒ©ÎﾡÔç½øÈëÁÙ´²½×¶Îµì¶¨Á˼áʵ»ù´¡¡£

ÔÚAIÖÆÒ©ÁìÓò£¬ÃÀµÏÎ÷ÓÚ2021ÄêÁªºÏ·¢Æð³ÉÁ¢ÕŽ­AIÐÂÒ©Ñз¢ÁªÃË£¬³Â´º÷벩ʿ³öÈÎÁªÃËÊ×½ìÂÖÖµÁªÏ¯Ö÷ϯ¡£ÎÒÃÇÒÑÓëÓ¢ÎùÖÇÄÜ¡¢µÂî£ÖÇÒ©¡¢ÉîÊƿƼ¼µÈ¶à¼ÒAI´´ÐÂÒ©Ñз¢¹«Ë¾´ï³ÉÕ½ÂÔºÏ×÷¡£

ÃÀµÏÎ÷ÓÚ8ÔÂ21ÈÕÌØÑûÒ©Îï´úл¶¯Á¦Ñ§²¿DMPK¸±Ö÷ÈÎ Íòßäßä×ö¿ÍÔƽ²Ì㬴øÀ´Ö±²¥¡¶LC-MS/MS¼¼ÊõÔڹѺËÜÕËáÀàÒ©ÎïÉúÎï·ÖÎöÖеÄÓ¦ÓÃ̽Ë÷Óëʵս²ßÂÔ¡·

µÚ¶þÊ®¶þ½ìÊÀ½çÖÆÒ©Ô­ÁÏÖйúÕ¹£¨CPHI China£©ôßµÚÊ®Æß½ìÊÀ½çÖÆÒ©»úе¡¢°ü×°É豸Óë²ÄÁÏÖйúÕ¹£¨PMEC China£©¡±½«ÔÚÉϺ£Ð¹ú¼Ê²©ÀÀÖÐÐÄÖØ°õÆôÄ»¡£ÃÀµÏÎ÷½«ÔÚW9¹Ý£¨ÖÆÒ©Ô­ÁÏ×ÛºÏÀࣩȫ³ÌÉèÕ¹£¬Õ¹Î»ºÅW9C80¡£

4ÔÂ17ÈÕ19:00-21:00£¬ÃÀµÏÎ÷Ìرð²ß»®ÁËÒ»³¡¹ØÓÚƤ·ôÍâÓÃÖƼÁÁÙ´²Ç°Ñо¿µÄÖ±²¥¡£±¾´ÎÖ±²¥½«ÑûÇëÔÚÖƼÁÑз¢ÁìÓò¾ßÓзḻ¾­ÑéµÄÓàСÀÚ¡¢²ÜÄȺÍÔ¬ÔÆÔÆ£¬ÎªÎÒÃÇ´øÀ´Ò»³¡¹ØÓÚƤ·ôÍâÓÃÖƼÁµÄÉî¶È½â¶ÁÓëÇ°ÑØ·ÖÏí¡£

ÃÀµÏÎ÷Ö´Ðи±×ܲüæÃÀ¹ú¹«Ë¾×ܲÃÁÖÇì´Ï²©Ê¿½«´øÁìÍŶӳöϯÓÚ4ÔÂ5ÈÕÔÚÃÀ¹úÊ¥µØÑǸç¾ÙÐÐÃÀ¹ú°©Ö¢Ñо¿Ð­»á£¨AACR£©Äê»á£¬Õ¹Î»ºÅ4021¡£

ÃÀµÏÎ÷Çë»Ø´ðΪÄú½²½âKRASÒÖÖƼÁµÄ·¢Õ¹Àú³Ì£ºKRAS Óë·Î°©µÄ¹ØϵÓÚ1984Äê±»Ê×´ÎÃèÊö£¬ÕâЩÄêKRAS Í»±äÔڷΰ©ÖÐÒѾ­ÓжàÏî½øÕ¹¡£2021Äê³É¹¦¿Æѧ¼ÒÃÇ¿ª·¢³ö×è¶ÏÍ»±äÐÍKRAS G12C µÄ¹²¼ÛÒÖÖƼÁ¡£

2023Äê9ÔÂ30ÈÕÖÐÇï¼Ñ½Ú£¬ÄϼÓÉúÎïҽѧºÍÖÆÒ©´Ù½ø»á (SABPA)³É¹¦¾Ù°ìÁ˵Ú21½ìÊ¥µØÑǸçÉúÎïÖÆÒ©ÂÛ̳£¬³Â´º÷벩ʿÊÜÑû·¢±íÁË¡°Retrospective Studies on New Drug Research in China based on IND Approval Cases at Medicilon¡±¾«²ÊÑݽ²¡£

ÃÀµÏÎ÷¹ú¼ÊÑз¢·þÎñ²¿Ö´Ðи±×ܲô÷ѧ¶«²©Ê¿ÓëÃÀµÏÎ÷ÃÀ¹úÍŶӳöϯÁË2023 ÄêDiscovery on Target (DOT)»áÒ飬ÔÚ221ºÅչ̨¶ÔÀ´·ÃÕßµÄËùÌáÎÊÌâ¾ù¸øÒÔÁËרҵÇÒÏêϸµÄ½â´ð£¬Óë¶àλ²Î»á¼Î±ö½øÐÐÁËÓäÔõÄÉî¶È½»Á÷¡£

ÃÀµÏÎ÷»ã×ÜÕûÀíÁË10ÔÂÉúÎïÒ½Ò©ÐÐÒµ»áÒ鹩²Î¿¼½»Á÷£¬ÎÒÃǽ«¼Æ»®²ÎÓë13th DRUG DISCOVERY Strategic Summit ¡¢2023ÖйúÒ©ÎﻯѧѧÊõ»áÒé ¡¢SDDA£¨ÖйúÐÂÒ©Ñз¢Ð­»á£©28ÆÚ»áÒéµÈº£ÄÚÍâ21³¡»áÒé¡£

ÃÀµÏÎ÷´´Ê¼ÈË&CEO³Â´º÷벩ʿ½«³öϯµÚ21½ìÊ¥µØÑǸçÉúÎïÖÆÒ©´ó»á£¬²¢´øÀ´Ö÷ÌâÑݽ²£º¡°Retrospective Studies on New Drug Research in China based on IND Approval Cases at Medicilon¡±

Uncovering new therapeutics for kidney fibrosis hold promise for chronic kidney disease (CKD). BRD4 inhibition ameliorated kidney injury and fibrosis. ZLD2218 exhibited the potent inhibitory activity

Phosphodiesterase-1 (PDE1) is a promising drug target closely related to central and peripheral diseases. Compound 2j with the IC50 of 21 nM against PDE1B, shows good metabolic stability in the rat li

ARD-2128 has excellent plasma and microsomal stability in all the five species (Human, Mouse, Rat, Dog, and Monkey). The in vitro stability and pharmacokinetic (PK) studies were performed by Medicilon.

The pharmacokinetic properties of TR©\107 were compared with other known ClpP activators including ONC201 and ONC212. TR©\107 displayed excellent exposure and serum t1/2 after oral administration. Pharmacokinetic analysis were evaluated for pharmacokinetic

The p21 activated kinase 4 (PAK4) is serine/threonine protein kinase that is critical for cancer progression. 6-Ethynyl-1H-indole derivative 55 is a potent and selective PAK4 inhibitor (Ki=10.2 nM). Compound 55 is effective in the treatment of metastatic

2023Äê6ÔÂ19-21ÈÕ£¬CPHI & PMEC ChinaÔÚÉϺ£Ð¹ú¼Ê²©ÀÀÖÐÐÄÔ²ÂúÂäÄ»¡£ ÃÀµÏÎ÷ÔÚÕ¹»áÏÖ³¡¾Ù°ìÁËÁ½³¡×¨ÌâÑÐÌÖ»á,ÒÔ¼°IDSUºÍµçÉÌÖмäÌåƽ̨·¢²¼»á£¬ÃÀµÏÎ÷¿ÆÑÐÍŶӴӶàÖØÊÓ½ÇÆë¾ÛΪ´ó¼Ò´øÀ´×¨ÒµµÄ¸É»õ»°Ìâ·ÖÏí£¬±ü³Ö"ÂÌÉ«»¯Ñ§"ÀíÄһվʽÇý¶¯ÐÂÒ©Ñз¢´´Ð·¢Õ¹¡£»î¶¯Í¨¹ý¡°ÏßÉÏ+ÏßÏ¡±µÄÐÎʽ£¬¹²Í¬Ì½ÌÖÉúÎïÒ½Ò©ÐÐҵвúÆ·+вßÂÔ £¬¾«×¼ÖúÁ¦ÉúÎïÒ½Ò©ÉÏÏÂÓÎÆóÒµÒµÎñ¸ßËÙÔö³¤£¡»¶Ó­¹Û¿´ÊÓƵ»Ø·Å

2023Äê6ÔÂ19-21ÈÕ£¬CPHI & PMEC ChinaÔÚÉϺ£Ð¹ú¼Ê²©ÀÀÖÐÐÄÔ²ÂúÂäÄ»¡£ ÃÀµÏÎ÷ÔÚÕ¹»áÏÖ³¡¾Ù°ìÁËÁ½³¡×¨ÌâÑÐÌÖ»á,ÒÔ¼°IDSUºÍµçÉÌÖмäÌåƽ̨·¢²¼»á£¬ÃÀµÏÎ÷¿ÆÑÐÍŶӴӶàÖØÊÓ½ÇÆë¾ÛΪ´ó¼Ò´øÀ´×¨ÒµµÄ¸É»õ»°Ìâ·ÖÏí£¬±ü³Ö"ÂÌÉ«»¯Ñ§"ÀíÄһվʽÇý¶¯ÐÂÒ©Ñз¢´´Ð·¢Õ¹¡£»î¶¯Í¨¹ý¡°ÏßÉÏ+ÏßÏ¡±µÄÐÎʽ£¬¹²Í¬Ì½ÌÖÉúÎïÒ½Ò©ÐÐҵвúÆ·+вßÂÔ £¬¾«×¼ÖúÁ¦ÉúÎïÒ½Ò©ÉÏÏÂÓÎÆóÒµÒµÎñ¸ßËÙÔö³¤£¡»¶Ó­¹Û¿´ÊÓƵ»Ø·Å

CPHI & PMEC China¼´½«ÓÚ2023Äê6ÔÂ19-21ÈÕÔÚÉϺ£Ð¹ú¼Ê²©ÀÀÖÐÐľÙÐУ¬ÃÀµÏÎ÷»¶Ó­ÄúÖÁÎÒ˾չ루E2D75£©²Î¹ÛǢ̸!

ÃÀµÏÎ÷2023Äê¶ÈÓ¢¹úÑÐÌÖ»á Medicilon¡¯s 2023 Annual UK Symposium: New Approaches to Facilitate Drug Discovery ½«ÓÚµ±µØʱ¼ä4ÔÂ21ÈÕÔÚÓ¢¹ú½£ÇſƼ¼Ô°°Í²¼À­ººÄ·Ñо¿Ô°Çø¾Ù°ì¡£